Galena Biopharma, Inc. (GALE) Presents Promising NeuVax™ Data at the 27th Annual Meeting of the Society of Immunotherapy and Cancer

Galena Biopharma, a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, recently finished presenting data from its Phase 1/2 clinical trial of NeuVax™ (nelipepimut-S or E75) at the 27th Annual Meeting of the Society of Immunotherapy and Cancer. Galena presented data from its research at the event, which was held on October 26-28, 2012, at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.

The poster presentation entitled: “Trends in Circulating Tumor Cells (CTCs) in Multiple Adjuvant Trials of HER2-Directed Peptide Vaccines (PVs)” measured CTC’s from blood samples from NeuVax™ (nelipepimut-S or E75) patients using the CellSearch® system (Veridex). Progress in this area is vital to ongoing cancer research so that CTC’s — cells that have detached from the primary breast tumor and then circulate in the bloodstream, which may then cause the growth of additional tumors (metastases) in different tissue — can be better understood and controlled, reducing the chance of further metastasization. The recurrence of CTC’s may occur soon after the original cancer or many years after initial treatment. Those individuals with higher levels of CTC’s are, therefore, at an increased risk of cancer recurrence, resulting in poor disease-free survival (DFS) and overall survival (OS), suggesting a dormancy of isolated micrometastases.

“Even with the major advances in earlier diagnoses and better treatment options, approximately 25% of resectable node-positive breast cancer patients will still relapse within three years, despite having no evidence of disease following surgery and chemotherapy/radiation treatment,” said Mark J. Ahn, Ph.D., Galena’s President and Chief Executive Officer. “The data presented today shows that treatment with NeuVax reduces CTCs and therefore may prevent growth of future micrometastasis, lending support to the idea of using the woman’s immune system to prevent relapse of her breast cancer.”

Additionally, Galena has kept busy with several presentations over the past month. Mark J Ahn, Ph.D., President and Chief Executive Officer, presented a corporate update at BioX: Noble Financial Capital Markets’ Life Sciences Exposition held at the University of Connecticut, Stamford Campus, on September 24, 2012. Immediately following, Mr. Ahn presented a corporate overview at the 2012 Aegis Capital Healthcare Conference, held at The Wynn in Las Vegas, NV, on September 28.

Galena Biopharma is focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics.

For more information on Galena Biopharma, visit www.galenabiopharma.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.comwww.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Pulse